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C57BL/6 genetically modified mouse models are the accepted gold standard in biological studies. However,
an increasing failure of translating the findings to human (patho)physiology casts doubt on using a single
strain to address many questions.The 2007 award of the Nobel Prize in
Physiology or Medicine for the use of
embryonic stem cells in the modification
of the mouse genome provides an oppor-
tune time for us to discuss the revolution-
izing power of targeted mutagenesis and
reminds us of its potential shortcomings.
Here, we deal with the issue of genetic
makeup in mouse models and its influ-
ence on specific phenotypes. In immunol-
ogy, as in other investigative sciences,
C57BL/6 mouse models are the most
frequently used. However, the lessons
learned from multiple studies caution
against extrapolation of the findings from
a single strain as relevant to human
(patho)physiology.
The mouse (Figure 1) is the primary
mammalian model organism because of
its close genetic relationship to humans
and the ease with which modification of
its genome can be used to study human
disease. The genetic pathways regulating
normal and pathological conditions in
these two species are quite conserved
despite some obvious physiological and
anatomical differences. Gene-targeted
mutagenesis in the mouse has enabled
the generation of models lacking specific
gene function, as well as the detailed
study of genetic mutations first identified
in human pathology (Evans et al., 2001).
For historical and practical reasons,
gene targeting hasbeenperformedmainly
in embryonic stem (ES) cells from the 129
mouse strains (Nagy and Vintersten,
2006). 129 ES cell lines are easy to derive
and can be manipulated in culture while
remaining competent to repopulate the
mouse germline. However, because 129
strains do not breed well and are reportedto have abnormal anatomy and behavior,
backcrossing of newly generated mutant
mice into the C57BL/6 background
is widely accepted. C57BL/6 is the
most widely used inbred strain because
these mice breed well, are long-lived,
and are permissive for expression of
most mutations (http://jaxmice.jax.org/
strain/000664.html). However, the use of
C57BL/6 mice also has its drawbacks
because they have a low susceptibility to
tumors, develop severe and progressive
hearing loss with onset after 10 months
of age, and demonstrate a skewing
toward T helper1 (Th1) responses (O’Neill
et al., 2000). This limits the use of this
strain for certain immunological questions,
in studies on tumorigenesis and raised the
awareness in behavioral neuroscience,
where sensory impairments (i.e., hearing
loss) can lead to poor performance inde-
pendently of the genetic mutation under
analysis (Crawley et al., 1997). Thus,
although most scientists believe that the
key to the proper interpretation of the
phenotype of amousewith a targetedmu-
tation lies in the purity of its genetic back-
ground and consider the pure C57BL/6
background as the gold standard, the
reality is far more complex (Frankel, 1998).
The Absence of an ‘‘Expected’’
Phenotype
The inability of scientists to produce
animal models with expected phenotypes
has often generated doubts as to whether
the emphasis on mouse models is mis-
placed and the physiological differences
between mice and humans is too pro-
found. Perhaps the relevant question is
whether we fail to perform our analysisImmunin the appropriate genetic conditions or
whether we expect that most human dis-
orders will manifest similarly in themouse.
An excellent example of the former is pro-
vided by the p53-deficient mouse. Given
the extensive in vitro evidence pointing
to key roles for p53 in initiating both
apoptosis and the cell cycle, it was quite
surprising that these mice were not em-
bryonic lethal (Donehower et al., 1992).
Moreover, the findings that they develop
mainly lymphomas, a type of tumor that
mice are particularly prone to develop,
appeared to be in contrast with the role
of p53 in a variety of other human tumors.
Eventually, closer inspection of p53-defi-
cient mice showed that developmental
abnormalities could be detected. More-
over, when crossed into different genetic
backgrounds, this mouse was demon-
strated to be a robust model, showing
similarities to humans in tumorgenesis
[reviewed in (Lozano and Liu, 1998)].
The absence of an expected phenotype
might also result from less well defined
physiological differences in humans and
mice. Fabry disease is caused by a-galac-
tosidaseAdeficiency. In humans, it results
in the deposition of neutral glycosphingo-
lipids containing a-linked galactosylmoie-
ties in the vascular endothelium, ultimately
causing renal failure, strokes, or prema-
ture myocardial infarctions. However,
whereasmice deficient ina-galactosidase
A exhibit lipid inclusions in lysososmes
and show a marked accumulation of neu-
tral glycosphingolipids in the liver and kid-
ney, they are clinically normal [reviewed in
(Thyagarajan et al., 2003)]. This difference
in the manifestation of disease might well
result from differences in the life span ofity 28, January 2008 ª2008 Elsevier Inc. 1
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span of the mouse, the accumulation of
the neutral glycosphingolipids might not
be sufficient to elicit the clinical symptoms
seen in humans. However, because a-ga-
lactosidase A deficiency in the mouse has
been studied only in the commonly used
genetic backgrounds (such as 129 and
C57BL/6), it is also possible that the
expected phenotype might be revealed
in another mouse strain.
Figure 1. What Is the Right Genetic
Background?
Shown are C57BL/6, 129/Sv, and BALB/c mice, as
well as chimeras derived from hybrid C57BL/
63129/Sv embryonic stem cells injected into
C57BL/6 and BALB/c blastocysts. An increasing
body of work suggests that we should explore mul-
tiple mouse strains when studying specific genes
to unravel the complex genetic interactions under-
lying their function and the development of specific
pathologies. This broader approach is likely to
enhance the relevance of the findings in mouse
models to human physiology and disease.Phenotypic Variance
The profound genetic differences be-
tween mouse strains, in addition to the
intrinsic mouse-human species diversity,
have further complicated translating the
findings in mouse models to human
disease. Since the first generation of ge-
netically modified mouse strains, it has
become apparent that not all isogenic
backgrounds are appropriate for a given
study. Indeed, the characteristics of cer-
tain isogenic strains can make them
poor mimics of human disease or even
overshadow the effects of the targeted
mutation. One example is the contrasting
degree of airway inflammation seen in
the ovalbumin (OVA) model of asthma in
BALB/c versus C57BL/6 mice. Once
sensitized to OVA, an aerosol challenge
of BALB/c mice with OVA is characterized
by a marked increase in lymphocytes,
eosinophils, and neutrophils in the bron-
choaveolar fluids, which is paralleled by
prominently elevated amounts of the2 Immunity 28, January 2008 ª2008 Elseviercytokines interleukin-4 (IL-4), IL-5, and
tumor necrosis factor (TNF). In contrast,
C57BL/6 mice show a much weaker in-
flammatory immune response in the lung
(Herz et al., 2004). Importantly, this might
manifest in a greater degree of airway hy-
perreactivity in the BALB/c mouse, more
closely mimicking human asthma relative
to C57BL/6 mice. In neither case, how-
ever, is there the marked remodeling of
the airways seen in human asthma.
The influence of genetic background on
a given phenotype can be quite striking.
Mast cells derived from C57BL/6 mice
carrying a null mutation for the Src family
tyrosine kinase (STK) Lyn showed a dra-
matic inhibition of degranulation relative
to their wild-type counterparts when chal-
lenged via Fc3RI. In contrast, mast cells
from 129/SvJ mice carrying the same
mutation showed an enhanced degranu-
lation response when compared to their
wild-type counterparts and to all C57BL/
6-derived mast cells (Yamashita et al.,
2007). A noted difference was lower
expression (50%) of the STK Fyn in the
C57BL/6-derived mast cells. This kinase
functions to promote degranulation
(Parravicini et al., 2002), and it was
demonstrated that ectopic expression in
C57BL/6 cells, in the context of Lyn defi-
ciency, caused reversion to a highly
responsive phenotype. Thus, the findings
showed that relatively small changes in
gene expression could cause marked
phenotypic changes. Importantly, silenc-
ing of Fyn or Lyn expression in human
mast cells demonstrated that Lyn func-
tions to inhibit mast cell degranulation,
whereas Fyn functions to promote it (Ya-
mashita et al., 2007). Thus, in this case,
it appears that the 129/SvJ mouse is a
better mimic for the role of these kinases
in human mast cells.
In behavioral studies, for the analysis
of the negative effect of gene loss in com-
plex learning, the use of a strain with
relatively good learning ability, such as
C57BL/6, or a hybrid, such as 129/Sv 3
C57BL/6 or 129/Sv 3 BALB/c, is prefer-
able to the pure 129/SvJ or BALB/c mice,
which are poor learners (Crawley et al.,
1997). The opposite is true for testing of
prepulse inhibition (PPI) to the acoustic
startle response, a behavioral paradigm
used for the evaluation of schizophrenic
behavior. In this case, 129/SvJ mice,
which have a good PPI, can be used for
the detection of behavioral phenotypesInc.of null mutations predicted to impair PPI,
whereas C57BL/6 mice, which have
poor PPI, can be used for the investiga-
tion of mutations postulated to improve
this response (Crawley et al., 1997). Al-
though these examples suggest a com-
plex relationship between behavioral
paradigm and genetic background, they
also indicate that we can use the genetic
background as a tool to expand the
use of the mouse to understand human
physiology.
Genetics and Viability
The influence of genetic background is
true not only for ‘‘mild’’ phenotypes as
behaviors, but also the viability of the
animal, as well. Examples of such an
effect are those of the transforming
growth factor-b1 (TGF-b1)- and epidermal
growth factor (EGF)-receptor-deficient
mice. Backcrossing of the mixed back-
ground TGF-b1-deficient mouse to the
C57BL/6 background causes complete
embryonic lethality (Kallapur et al.,
1999). In a mixed 129 3 CF1 (50:50)
or C3H background, embryonic lethality
is observed around 50% of the time,
whereas in BALB/c, it is only observed
20% of the time. In a more extreme sce-
nario, EGF-receptor-deficient mice show
profound variation in survival, ranging
from peri-implantation to postnatal lethal-
ity, depending on the strain of the devel-
oping embryos (Sibilia and Wagner,
1995; Threadgill et al., 1995). Obviously,
striking changes in background-related
viability questions the relevance of any
findings in such models to humans. Nev-
ertheless, we are now learning important
lessons even from mice with extreme
phenotypes. For example, the EGF-re-
ceptor-deficient mice can be used to pre-
dict molecule-targeted therapy toxicity in
cancer patients because some of the phe-
notypes developed by these mutants are
remarkably similar to those shown by
patients chronically treated with EGF-
receptor inhibitors (Roberts et al., 2004).
Interestingly, although these appear to
be extreme examples of genetic-back-
ground influence on specific phenotypes,
they might instead represent the norm
when human pathological conditions are
considered. It is not uncommon that one
individual with a specific genetic mutation
develops a disease during his/her lifetime,
whereas another with the same mutation
will not. A classic case is that of mutations
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are associated with a relatively high risk
of developing breast and ovarian cancer.
Yet, only a subset of individuals with these
mutations will develop cancer (King et al.,
2003).
Adopting New Approaches
and Changing of Philosophy
How can we approach this genotype-to-
phenotype challenge in a mouse model?
Introduction of the mutation in mice of
a different genetic background might pro-
vide a tool for understanding the Mende-
lian inheritance of susceptibility to a com-
mon, genetically complex, adult-onset
disease (Davie et al., 2007; Qiu et al.,
2004). Comparison of the gene-expres-
sion profile of tumors with a similar ge-
netic mutation, but from mouse strains
having different metastatic incidence,
have already led to the identification of
genes that have been reported to be the
signature gene set predictive of metasta-
sis in human tumor (Qiu et al., 2004; Ram-
aswamy et al., 2003). Thus, it appears that
the answer for themodeling of human dis-
ease is not linked exclusively to the use of
a specific genetic mutation in a mouse
strain but to the combined use of the mu-
tation and different genetic backgrounds.
This approach has also been facilitated by
development of new tools for defining the
genetic background of an inbred strain
(Ridgway et al., 2007). The availability of
genomic sequence for 11 inbred labora-
tory strains and four ‘‘wild-derived’’
strains (including C57BL/6 and 129) has
allowed the comparison of their haplo-
types, revealing more than 8 million
single-nucleotide polymorphisms (SNPs)
in the mouse genome. This now enables
the investigator to compare key differ-
ences in the strains used and to define
loci of interest that might be further ex-
plored for their influence on the observed
phenotype.
Clearly, practical reasons, including the
costs of performing background crosses,
make it difficult to introduce a genetic
mutation in multiple mouse strains. Irre-
spective of these reasons, immunologists
have been particularly resistant to this
approach and have instead been strong
advocates of the pure C57BL/6 genetic
background. The reductionist approach
has the advantage of getting direct infor-
mation on the role of a gene function
and makes it easier to compare the effectof a gene with existing data. However, the
real questions are whether we might miss
valuable information by rigidly limiting
ourselves to a single genetic background
and whether we can extrapolate those
findings to the human population, which
is extremely heterogenous by nature. It
is becoming obvious that analysis of a
mutation in multiple backgrounds might
be a necessity for immunology. For exam-
ple, the human natural killer cell Ig-like
receptor (KIR) family is highly polymorphic
because of variable gene content of indi-
vidual haplotypes and a great degree
of allelic diversity. This variability can in
part explain the individual diversity in the
response to pathogens or allergic reac-
tions. The murine Ly49 gene family is
functionally homologous to the KIR family
in humans (Makrigiannis et al., 2002). In
terms of genomic organization and com-
plexity, 129, C57BL/6, andBALB/c strains
have very different Ly49 haplotypes that
are functionally reflected in profound
differences in a variety of immune re-
sponses, including sensitivity to infection
with Sendai virus andmurine cytomegalo-
virus, susceptibility to the induction of
experimental systemic lupus erythemato-
sus, and experimental autoimmune en-
cephalomyelitis, bone-marrow-transplant
rejection, and carcinogen-induced tumor-
igenesis. These differences in immune
status and susceptibility to disease have
encouraged the use of specific mouse
strains in relation to the experimental
application. In fact, the diversity in Ly49
gene numbers between inbred mouse
strains is analogous to the haplotype
differences observed in the human KIR
genes, suggesting that different inbred
strains can provide an excellent source
of animal models for a wide spectrum of
disease and conditions because, like
humans, they differ at multiple genomic
sites and are extremely phenotypically
diverse.
The Dilemma
The dilemma is how we can approach the
study of genetic variability in an informa-
tive and yet economically feasible way.
We have no clear-cut answer. However,
it appears that we should not put so
much emphasis on and invest exclusively
into the making of mouse mutants from
pure C57BL/6 ES cell lines. These lines
do not perform well, and they might give
the false illusion of the ‘‘perfect system.’’ImmunInstead, we should expand the use of
hybrid ES cell lines. Hybrid ES cell lines
derived, for example, from F1 inter-
crosses of 129 3 C57BL/6 or 129 3
BALB/c mice, retain the 129 characteris-
tics of easy derivation and ability to be
manipulated in culture while remaining
competent to repopulate the mouse
germline (You et al., 1998). They allow
study of the effects of genetic heteroge-
neity observed in the human population.
Yet, they also permit one to obtain a spe-
cific genetic mutation in a congenic strain
of interest. For example, if a mutation is
needed in the C57BL/6 background, a hy-
brid 1293C57BL/6 ES cell line can still be
used for gene targeting with a C57BL/6
DNA vector. This will favor the targeting
of the C57BL/6 allele, making it easier to
obtain a pure congenic line with all genes
surrounding the targeted area coming
from this strain. This was not possible
when ES cells from a pure 129 strain
were used because even with repeated
backcrosses into the C57BL/6 back-
ground, the null mutation will still be
flanked by two 129-derived alleles,
whereas the wild-type locus is flanked
by two C57BL/6 alleles. Generally, the
genes linked to the targeted locus are
not a problem. However, when the muta-
tion affects flanking genes or vice versa,
the result of the analysis of the null muta-
tion can lead to unexpected conclusions
(McVicar et al., 2002; Valor and Grant,
2007; Wolfer et al., 2002).
Overall, the examplesmentioned above
clearly suggest that the emphasis on
mousemodels is not misplaced. Targeted
mutagenesis in the mouse has provided
a tool for the study of human physiology
or disease and has revolutionized immu-
nology, cancer biology, neuroscience,
behavioral science, and many other disci-
plines. In contrast, the cited examples
also underscore the importance of ge-
netic heterogeneity in the investigation of
the genetic basis underlying the pene-
trance of specific phenotypes and sug-
gest that there is no gold standard in the
use of one specific mouse strain (Frankel,
1998). Thus, we should keep in mind that
the construction and propagation of a
mutant mouse must address not only the
single gene mutation but also the genetic
background. Rushed conclusions based
on limited data or from observations
made from mutations introduced into
a single (pure or mixed) geneticity 28, January 2008 ª2008 Elsevier Inc. 3
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Commentarybackground can be misleading and slow
the quest for new findings.REFERENCES
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